Krystal Biotech/$KRYS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Krystal Biotech
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
- Ticker
- $KRYS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 295
- Headquarters
- Pittsburgh, United States
- Website
- www.krystalbio.com
Krystal Biotech Metrics
BasicAdvanced
$9.8B
41.69
$7.97
0.54
-
Price and volume
Market cap
$9.8B
Beta
0.54
52-week high
$382.54
52-week low
$179.19
Average daily volume
281K
Financial strength
Current ratio
8.318
Quick ratio
7.726
Long term debt to equity
0.005
Total debt to equity
0.007
Profitability
EBITDA (TTM)
199.293
Gross margin (TTM)
94.64%
Net profit margin (TTM)
54.82%
Operating margin (TTM)
44.89%
Effective tax rate (TTM)
-6.55%
Revenue per employee (TTM)
$1,490,000
Management effectiveness
Return on assets (TTM)
9.37%
Return on equity (TTM)
20.12%
Valuation
Price to earnings (TTM)
41.687
Price to revenue (TTM)
22.026
Price to book
7.23
Price to tangible book (TTM)
7.23
Price to free cash flow (TTM)
37.637
Free cash flow yield (TTM)
2.66%
Free cash flow per share (TTM)
8.823
Growth
Revenue change (TTM)
22.63%
Earnings per share change (TTM)
62.40%
3-year earnings per share growth (CAGR)
13.71%
What the Analysts think about Krystal Biotech
Analyst ratings (Buy, Hold, Sell) for Krystal Biotech stock.
Analyst projections of the future price of Krystal Biotech stock.
Bulls say / Bears say
VYJUVEK brought in $119.2 million of global revenue in the second quarter, up 24% year on year, with a 95% gross margin. That gives Krystal a profitable commercial base to fund its growth. (GlobeNewswire)
VYJUVEK’s UK marketing authorisation adds another market, and Krystal expects to pursue further applications in Switzerland and Australia while targeting launches in Italy and Spain. Wider access creates room for sales growth beyond the US, although reimbursement discussions remain in progress. (GlobeNewswire, GlobeNewswire)
Krystal has two registrational studies under way and expects several pipeline readouts, with further programmes potentially advancing into registrational development in 2027. Its cash and investments of more than $1.1 billion provide funding to pursue these opportunities without an immediate need for outside financing. (The Motley Fool, GlobeNewswire)
European sales are exposed to uncertain payer negotiations: a German pricing reserve weighed on reported revenue, while discussions in France are expected to continue into 2027. Unfavourable terms or further delays could constrain the benefit from international expansion. (GlobeNewswire, Longbridge)
Management said US utilisation is around 50–60% and expects revenue to keep rising, but at a slower rate than during the initial launch. That suggests the US business may no longer deliver its earliest growth pace. (StockAnalysis)
VYJUVEK remains the company’s sole commercial revenue source, while the other programmes are still in development. Until pipeline candidates produce successful data and reach market, Krystal remains reliant on one product for sales. (GlobeNewswire, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2026.
Krystal Biotech Financial Performance
Revenues and expenses
Krystal Biotech Earnings Performance
Company profitability
Upcoming events
No upcoming events
Krystal Biotech News
AllArticlesVideos
Funds containing Krystal Biotech
AllUSDGBPEUR
Fund name | Fund size | $KRYS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.65% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.65% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.29% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.29% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.26% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.